Farhat Mirna H, Barada Kassem A, Tawil Ayman N, Itani Doha M, Hatoum Hassan A, Shamseddine Ali I
Division of Hematology-Oncology, Internal Medicine, Department of Pathology, American University of Beirut, 11-0236-Tumor registry, Riad El-Solh, Beirut 11070720, Lebanon.
World J Gastroenterol. 2008 Dec 7;14(45):6981-5. doi: 10.3748/wjg.14.6981.
To investigate the impact of mucin production on prognosis in colorectal cancer, in terms of overall survival (OS) and time to disease progression (TTP) in patients with mucinous compared to those with non-mucinous colorectal cancer (NMCRC), matched for age, gender, and tumor stage.
Thirty five patients with mucinous colorectal cancer (MCRC) were matched for age, gender, and tumor stage with 35 controls having NMCRC. OS and TTP were compared among 4 groups divided according to mucin content: group A (50%-75% mucin), group B (75%-100% mucin), group C or controls (<50% mucin). Group D consisted of all patients with tumors having <75% mucin (controls and groups A together).
Median survival in MCRC and NMCRC groups was 46.2 and 112.9 mo, respectively (P=0.26). OS in groups A and B was 70.1 and 32.8 mo (P=0.46), and in groups B and D was 32.8 and 70.1 mo, respectively (P=0.143). TTP in MCRC and NMCRC was 50.17 and 44.77 mo, respectively (P=0.795). TTP in groups A, B, and D was 70.1, 24.8, and 65.5 mo, respectively. Twenty-eight percent of patients with MCRC had poorly differentiated adenocarcinoma versus 8.6% in NMCRC patients (P=0.028).
MCRC is associated with a non-significant decrease in median survival and TTP, particularly when mucin content is >75% of tumor volume. However, it tends to be more poorly differentiated. A larger study matching for stage and grade is needed.
在年龄、性别和肿瘤分期相匹配的情况下,比较黏液性结直肠癌与非黏液性结直肠癌(NMCRC)患者的总体生存率(OS)和疾病进展时间(TTP),以研究黏液产生对结直肠癌预后的影响。
35例黏液性结直肠癌(MCRC)患者在年龄、性别和肿瘤分期方面与35例NMCRC对照患者进行匹配。根据黏液含量将患者分为4组进行OS和TTP比较:A组(黏液含量50%-75%)、B组(黏液含量75%-100%)、C组或对照组(黏液含量<50%)。D组由所有肿瘤黏液含量<75%的患者组成(对照组和A组合并)。
MCRC组和NMCRC组的中位生存期分别为46.2个月和112.9个月(P=0.26)。A组和B组的OS分别为70.1个月和32.8个月(P=0.46),B组和D组的OS分别为32.8个月和70.1个月(P=0.143)。MCRC组和NMCRC组的TTP分别为50.17个月和44.77个月(P=0.795)。A组、B组和D组的TTP分别为70.1个月、24.8个月和65.5个月。28%的MCRC患者为低分化腺癌,而NMCRC患者中这一比例为8.6%(P=0.028)。
MCRC与中位生存期和TTP的非显著性降低相关,尤其是当黏液含量超过肿瘤体积的75%时。然而,它往往分化程度更低。需要进行一项更大规模的按分期和分级匹配的研究。